Ronald Hoffman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9675443/publications.pdf

Version: 2024-02-01

160	3,455	159358	168136
papers	citations	30 h-index	53 g-index

163	163	163	3493
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematology,the, 2022, 9, e38-e48.	2.2	15
2	The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice. Frontiers in Oncology, 2022, 12, 853484.	1.3	7
3	Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasmâ€“blast phase. JCI Insight, 2022, 7, .	2.3	3
4	Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.. Journal of Clinical Oncology, 2022, 40, 7003-7003.	0.8	14
5	Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. Acta Haematologica, 2021, 144, 48-57.	0.7	11
6	LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discovery, 2021, 11, 1398-1410.	7.7	29
7	Recent advances in prognostication and treatment of polycythemia vera. Faculty Reviews, 2021, 10, 29.	1.7	2
8	What are the molecular mechanisms driving the switch from MPNs to leukemia?. Best Practice and Research in Clinical Haematology, 2021, 34, 101254.	0.7	3
9	The New Science and Concepts That Underlie Current and Future Treatments for Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, xvii-xix.	0.9	0
10	Overview of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 159-176.	0.9	18
11	Pleckstrin-2 is essential for erythropoiesis in Î²-thalassemic mice, reducing apoptosis and enhancing enucleation. Communications Biology, 2021, 4, 517.	2.0	8
12	Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic. Blood Reviews, 2021, 50, 100853.	2.8	20
13	The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica, 2021, 106, 2813-2823.	1.7	7
14	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of Clinical Oncology, 2021, 39, 2881-2892.	0.8	59
15	Evaluation of a clinical-grade, cryopreserved, ex vivo-expanded stem cell product from cryopreserved primary umbilical cord blood demonstrates multilineage hematopoietic engraftment in mouse xenografts. Cytotherapy, 2021, 23, 841-851.	0.3	6
16	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research, 2021, 109, 106629.	0.4	3
17	Potent In Vitro Peptide Antagonists of the Thrombopoietin Receptor as Potential Myelofibrosis Drugs. Advanced Therapeutics, 2021, 4, 2000241.	1.6	1
18	Ex Vivo Expansion of Adult Hematopoietic Stem and Progenitor Cells with Valproic Acid. Methods in Molecular Biology, 2021, 2185, 267-280.	0.4	17

#	Article	IF	Citations
19	Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells. Leukemia, 2021, , .	3.3	1
20	Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatric Blood and Cancer, 2021, 68, e28888.	0.8	7
21	Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients. Blood, 2021, 138, 57-57.	0.6	0
22	Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model. Blood, 2021, 138, 3591-3591.	0.6	5
23	European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. Blood, 2021, 138, 240-240.	0.6	3
24	Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy. Blood, 2021, 138, 390-390.	0.6	11
25	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera. Blood, 2021, 138, 1504-1504.	0.6	16
26	Development of an MDM2 Degrader for Treatment of Acute Leukemias. Blood, 2021, 138, 1866-1866.	0.6	3
27	Treatment of Myelofibrosis Patients with the TGF-Î² 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production. Blood, 2021, 138, 142-142.	0.6	10
28	Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials. Expert Opinion on Emerging Drugs, 2021, 26, 351-362.	1.0	3
29	Ex vivo HSC expansion challenges the paradigm of unidirectional human hematopoiesis. Annals of the New York Academy of Sciences, 2020, 1466, 39-50.	1.8	38
30	Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience. European Journal of Haematology, 2020, 104, 72-73.	1.1	14
31	Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia and Lymphoma, 2020, 61, 660-667.	0.6	18
32	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Advances, 2020, 4, 5246-5256.	2.5	45
33	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21
34	Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood, 2020, 135, 1696-1703.	0.6	54
35	Modern management of splenomegaly in patients with myelofibrosis. Annals of Hematology, 2020, 99, 1441-1451.	0.8	15
36	Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor. Stem Cells Translational Medicine, 2020, 9, 531-542.	1.6	34

#	Article	IF	Citations
37	Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia. Frontiers in Oncology, 2020, 10, 636675.	1.3	5
38	PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients. Blood, 2020, 136, 33-35.	0.6	10
39	Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients. Blood, 2020, 136, 40-41.	0.6	5
40	Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. Blood, 2020, 136, 39-40.	0.6	9
41	Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study. Blood, 2020, 136, 33-34.	0.6	1
42	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. Blood, 2020, 136, 1-1.	0.6	3
43	Rationale for and Results of a Phase I Study of the TGF-Î² 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. Blood, 2020, 136, 6-8.	0.6	8
44	Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 592348.	1.8	8
45	Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy. Blood, 2020, 136, 18-20.	0.6	0
46	Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019. Blood, 2020, 136, 37-37.	0.6	2
47	Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials. Blood, 2020, 136, 19-21.	0.6	0
48	Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. Blood, 2020, 136, 45-46.	0.6	21
49	Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery, 2019, 9, 1192-1207.	7.7	65
50	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	13.7	206
51	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Experimental Hematology, 2019, 79, 16-25.e3.	0.2	8
52	Preâ€clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice. Transfusion, 2019, 59, 3698-3713.	0.8	9
53	Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Scientific Reports, 2019, 9, 16609.	1.6	16
54	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	0.6	123

#	Article	IF	Citations
55	Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1343-1345.	0.6	17
56	Oral idasanutlin in patients with polycythemia vera. Blood, 2019, 134, 525-533.	0.6	67
57	Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34⁺ Cells Using Valproic Acid. Journal of Visualized Experiments, 2019, , .	0.2	17
58	Mitochondrial Role in Stemness and Differentiation of Hematopoietic Stem Cells. Stem Cells International, 2019, 2019, 1-10.	1.2	56
59	The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Reports in Hematology, 2019, 2019, 1-3.	0.3	7
60	Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 256-264.	2.0	47
61	New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica, 2019, 104, 3-6.	1.7	17
62	Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database. Blood, 2019, 134, 2949-2949.	0.6	2
63	Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms. Blood, 2019, 134, 4194-4194.	0.6	2
64	Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells. Blood, 2019, 134, 2963-2963.	0.6	4
65	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÃ¯ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	0.6	21
66	The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells. Blood, 2019, 134, 1677-1677.	0.6	1
67	A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells. Blood, 2019, 134, 4201-4201.	0.6	2
68	A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).. Journal of Clinical Oncology, 2019, 37, 7056-7056.	0.8	6
69	Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera. Blood, 2019, 134, 429-429.	0.6	2
70	Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials. Blood, 2019, 134, 1661-1661.	0.6	0
71	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	3.4	261
72	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415

#	Article	IF	Citations
73	Don't judge a JAK2 inhibitor by spleen response alone. Lancet Haematology,the, 2018, 5, e56-e57.	2.2	2
74	Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports, 2018, 8, 6587.	1.6	5
75	Current approaches to challenging scenarios in myeloproliferative neoplasms. Expert Review of Anticancer Therapy, 2018, 18, 567-578.	1.1	5
76	Novel treatments to tackle myelofibrosis. Expert Review of Hematology, 2018, 11, 889-902.	1.0	1
77	The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Advances, 2018, 2, 1130-1145.	2.5	16
78	Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Advances, 2018, 2, 3572-3580.	2.5	51
79	Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Advances, 2018, 2, 2378-2388.	2.5	39
80	Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia, 2018, 32, 2105-2116.	3.3	84
81	Whirling Platelets Away for Transfusion. Cell, 2018, 174, 503-504.	13.5	5
82	Genomic characterization of spleens in patients with myelofibrosis. Haematologica, 2018, 103, e446-e449.	1.7	7
83	Modeling Calreticulin-Mutant Myeloproliferative Neoplasms with Isogenic Induced Pluripotent Stem Cells. Blood, 2018, 132, 4319-4319.	0.6	3
84	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	0.6	6
85	Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial). Blood, 2018, 132, 3027-3027.	0.6	5
86	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	0.6	39
87	Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. Blood, 2018, 132, 685-685.	0.6	33
88	Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells. Blood, 2018, 132, 101-101.	0.6	4
89	A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF). Blood, 2018, 132, 5481-5481.	0.6	10
90	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. Blood, 2018, 132, 5784-5784.	0.6	0

#	Article	IF	Citations
91	Enriched Populations of Human Megakaryocytic Cells Affect the Behavior of Myelofibrosis CD34+ Cells As Well As Cells Belonging to the MF Supportive Microenvironment. Blood, 2018, 132, 3057-3057.	0.6	0
92	High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations. Blood, 2018, 132, 541-541.	0.6	1
93	Infusion of a Cryopreservable Human Megakaryocyte-Biased Cell Product Results in Sustained Platelet Reconstitution In Vivo. Blood, 2018, 132, 117-117.	0.6	0
94	Outcomes of Abdominal Thrombosis in Patients with Myeloproliferative Neoplasms in a Single Center Experience. Blood, 2018, 132, 4307-4307.	0.6	0
95	A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia Research, 2017, 53, 13-19.	0.4	35
96	Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. Cancer Research, 2017, 77, 164-174.	0.4	10
97	The Exhaustion of Adult Hematopoietic Stem Cells in Ex Vivo Cultures Can Be Overcome by a Histone Deacetylase Inhibitor. Blood, 2017, 130, 655-655.	0.6	3
98	Outcome Disparities in Caucasian andÂNon-Caucasian Patients With Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 350-357.	0.2	14
99	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 2180-2186.	2.0	20
100	A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood, 2016, 127, 3398-3409.	0.6	22
101	Preclinical rationale for TGF-Î² inhibition as a therapeutic target for the treatment of myelofibrosis. Experimental Hematology, 2016, 44, 1138-1155.e4.	0.2	38
102	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica, 2016, 101, 660-671.	1.7	120
103	Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e133-e137.	0.2	10
104	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2301-2301.	0.6	1
105	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	0.6	32
106	Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies. Blood, 2016, 128, 818-818.	0.6	4
107	Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis. Blood, 2016, 128, 953-953.	0.6	4
108	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/Âµl. Blood, 2016, 128, LBA-5-LBA-5.	0.6	29

#	Article	IF	Citations
109	The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.. Journal of Clinical Oncology, 2016, 34, TPS7079-TPS7079.	0.8	0
110	Transcriptional Characterization of Myelofibrotic Bone Marrow Microenvironment Reveals Distinct Tumor Microenvironment in JAK2+ and Calr+ PMF Marrows. Blood, 2016, 128, 1954-1954.	0.6	0
111	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Research, 2015, 39, 157-163.	0.4	28
112	Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood, 2015, 126, 972-982.	0.6	58
113	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2543-2551.	0.6	29
114	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of Clinical Oncology, 2015, 33, 3953-3960.	0.8	69
115	Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis. Blood, 2015, 126, 1618-1618.	0.6	8
116	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. Blood, 2015, 126, 56-56.	0.6	28
117	Digital Immune Expression Profiling Coupled with Immunohistochemistry for Interrogation of Microenvironment in Formalin Fixed Paraffin Embedded Specimens of Marrow and Spleen from PMF Patients. Blood, 2015, 126, 2832-2832.	0.6	3
118	An Inhibitor of TGF-Î² Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations. Blood, 2015, 126, 4089-4089.	0.6	0
119	The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells. Blood, 2015, 126, 5216-5216.	0.6	0
120	Characterization and Isolation of Splenic Littoral Cells, a Possible Cellular Niche for Extramedullary Hematopoiesis in Myelofibrosis. Blood, 2015, 126, 3594-3594.	0.6	0
121	Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 31-36.	0.2	34
122	Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Experimental Hematology, 2014, 42, 137-145.e5.	0.2	68
123	Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica, 2014, 99, 945-949.	1.7	24
124	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 2014, 124, 1183-1191.	0.6	135
125	The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon Î± 2a target JAK2V617F-positive progenitor and stem cells. Blood, 2014, 124, 771-779.	0.6	58
126	JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood, 2014, 124, 2987-2995.	0.6	28

#	Article	IF	Citations
127	Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia. Blood, 2014, 124, 3206-3206.	0.6	2
128	Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.. Journal of Clinical Oncology, 2014, 32, 7114-7114.	0.8	1
129	The Effects of Lipocalin (LCN2) on Hematopoiesis in Primary Myelofibrosis. Blood, 2014, 124, 1878-1878.	0.6	0
130	Prevalence Of The JAK2V617F Mutation and Associated Risk Haplotype and Determination Of Demographic and Lifestyle Risk Factors In The US Population, Nhanes 1999-2002. Blood, 2013, 122, 391-391.	0.6	0
131	Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-Î± 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood, 2012, 120, 3098-3105.	0.6	55
132	p53 as a target in myeloproliferative neoplasms. Oncotarget, 2012, 3, 1052-1053.	0.8	6
133	Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,. Blood, 2011, 118, 3526-3526.	0.6	0
134	Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis. Blood, 2011, 118, 4534-4534.	0.6	0
135	Rational therapeutic options for patients with myeloproliferative neoplasms. Transactions of the American Clinical and Climatological Association, 2011, 122, 11-26.	0.9	0
136	Chromatin Modifying Agents Promote the Ex Vivo Production of Functional Human Erythroid Progenitor Cells. Blood, 2010, 116, 340-340.	0.6	1
137	Inversion of Chromosome 12 and Translocations of 12q13-q15 In Primary Myelofibrosis (PMF) Are Associated with Disease Progression and a Poor Prognosis. Blood, 2010, 116, 4110-4110.	0.6	1
138	Recurrent Amplified Regions on the Long Arm of Chromosome 1 (1q) Are Associated with Disease Progression In Ph-Negative Myeloproliferative Neoplasms (MPN). Blood, 2010, 116, 3087-3087.	0.6	0
139	The A3669G Polymorphism of GR Is a Host Genetic Modifier Associated with Polycythemia Vera and Primary Myelofibrosis. Blood, 2010, 116, 3067-3067.	0.6	0
140	Targeting Non-Histone Protein Acetylation Impairs Platelet Production During Normal Megakaryocytopoiesis.. Blood, 2010, 116, 2610-2610.	0.6	0
141	A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. Blood, 2009, 114, 308-308.	0.6	17
142	Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera.. Blood, 2009, 114, 3916-3916.	0.6	1
143	Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells.. Blood, 2009, 114, 752-752.	0.6	1
144	An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients.. Blood, 2009, 114, 753-753.	0.6	22

#	Article	IF	Citations
145	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. Blood, 2009, 114, 754-754.	0.6	19
146	Bone Marrow CD34+ Cells Expanded On Human Brain Endothelial Cells Reconstitutes Lethally Irradiated Baboons in a Variable Manner.. Blood, 2009, 114, 3214-3214.	0.6	0
147	Effective Management of Patients with Leukemic Transformation of Myelofibrosis.. Blood, 2009, 114, 4967-4967.	0.6	0
148	Sequential Treatment of CD34+ Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells.. Blood, 2009, 114, 1910-1910.	0.6	0
149	Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro.. Blood, 2009, 114, 1978-1978.	0.6	0
150	Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).. Blood, 2009, 114, 1567-1567.	0.6	0
151	Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin Modifying Agents. Blood, 2008, 112, 101-101.	0.6	3
152	Mast Cells Are Involved by the Malignant Process and Play An Important Role in the Pruritogenesis in Patients with Myeloproliferative Disorders. Blood, 2008, 112, 3729-3729.	0.6	1
153	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. Blood, 2008, 112, 98-98.	0.6	29
154	The JAK2V617F Mutation Is Present in the Liver Endothelial Cells of Patients with Budd-Chiari Syndrome. Blood, 2008, 112, 2795-2795.	0.6	0
155	Primary Myelofibrosis Is Associated with Truncation of the Plasma Chemokine SDF-1. Blood, 2008, 112, 3731-3731.	0.6	0
156	The Relationship Between Chromosomally Abnormal Hematopoiesis and the JAK2V617F Allele Burden in Patients (pts) with Ph-Negative Chronic Myeloproliferative Disorders (Ph-neg MPD). Blood, 2008, 112, 3106-3106.	0.6	0
157	Biology and Treatment of Primary Myelofibrosis. Hematology American Society of Hematology Education Program, 2007, 2007, 346-354.	0.9	37
158	Two Classes of Progenitor Cells in Patients with Myeloproliferative Disorders Are Capable of Generating JAK2V617F+CD31+CD144+ Endothelial Cells.. Blood, 2007, 110, 261-261.	0.6	0
159	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. Blood, 2007, 110, 3540-3540.	0.6	39
160	Association of 5qâ˜ and refractory anemia. American Journal of Hematology, 1978, 4, 269-272.	2.0	22